Search the Newsreel

Capricor Therapeutics (CAPR) to Post Earnings on Tuesday

Capricor Therapeutics (NASDAQ:CAPR) is scheduled to release its Q2 2026 earnings after market close on Tuesday, August 11th, with analysts forecasting a loss of $0.58 per share and revenue of $2.08 million. The company's stock has seen a significant decline due to regulatory concerns …

Americold Realty Trust Inc. $COLD Shares Sold by Royal Bank of Canada

Marico Q1 results: Net profit rises 25% YoY to ₹630 crore, revenue climbs 23%; check key numbers

Marico Q1 results: Profit jumps 27%, beats estimates on strong revenue and margin performance

CAPR Stock Drop: Capricor Therapeutics Clinical Data Leads to 64% Stock Drop and Securities Fraud Class Action for Investors

A class action lawsuit has been filed against Capricor Therapeutics, Inc. and its executives for securities fraud following a significant 64% stock drop. The lawsuit alleges Capricor made false statements regarding Deramiocel and the integrity of its clinical data, specifically concerning undisclosed changes to …

Renaissance Technologies LLC Has $7.46 Million Stock Position in TriCo Bancshares $TCBK

Capricor’s Duchenne AdCom Didn’t Fail on Science. It Failed on Statistics.

Capricor Therapeutics' deramiocel for Duchenne muscular dystrophy faced a decisive 9-3 rejection from an FDA advisory committee, despite its Phase 3 study meeting primary and secondary endpoints. The failure stemmed not from the therapy's scientific signal, but from unresolved statistical issues and concerns over …

Capricorn Metals (ASX:CMM) Extends Rally as Gold Stocks Continue to Command Investor Attention

Q1 Results: Bharti Airtel, ONGC, Pidilite, BSE, Marico, Nykaa, MCX, Tata Investment Corp, others to declare earnings on August 4; check list

Pricol Ltd (BOM:540293) (Q1 2027) Earnings Call Highlights: Revenue Surges 23% as Demerger ...

Credit Agricole SA (CRARF) (Q2 2026) Earnings Call Highlights: Record Revenues and Strategic ...

This article first appeared on GuruFocus. Net Income (CASA): EUR2.1 billion for Q2 2026, up 1.4% on a proforma basis. Revenue (CASA): Record EUR7.4 billion, up 7.7% quarter over quarter. Cost-to-Income Ratio (CASA H1 2026): 54.7%, down 1.2 percentage points H1 over H1. Return …

INVESTOR ALERT: Securities Class Action Filed Against Capricor Therapeutics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP

A class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased stock between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made misleading statements regarding changes to the statistical analysis plan for …

Investigation into Americold Realty Trust for Securities Violations

Schall, Brown & Schwartz LLP is investigating Americold Realty Trust for potential securities violations, focusing on whether the company made misleading statements to investors. This investigation follows Americold's disclosure of a termination agreement with ADUSA Distribution, leading to the closure of an automated retail …

CAPR Class Action Lawsuit FILED: Capricor Therapeutics Sued for Securities Fraud after Stock Drops 64% Leading to Securities Fraud Case – Investors Urged to Contact BFA Law

A class action lawsuit has been filed against Capricor Therapeutics, Inc. for securities fraud, alleging the company made false statements about its product Deramiocel and the integrity of its clinical data, leading to a significant stock drop. The lawsuit claims Capricor failed to disclose …

RA Capital discloses 3.0M-share Capricor stake in Schedule 13G filing (CAPR)

RA Capital Healthcare Fund, advised by RA Capital Management, has reported a beneficial ownership of 3,014,183 shares of Capricor Therapeutics, Inc. common stock, representing 5.2% of the outstanding shares. While RA Capital has been delegated sole power to vote and dispose of these shares, …

Rosen Law Firm Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Rosen Law Firm has announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made misleading statements regarding changes to the statistical analysis …

Law Offices of Frank R. Cruz Encourages Capricor Therapeutics, Inc. (CAPR) Shareholders To Inquire About Securities Fraud Class Action

The Law Offices of Frank R. Cruz has filed a class action lawsuit against Capricor Therapeutics, Inc. (CAPR) on behalf of shareholders who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges the company made misleading statements regarding changes to …

Deadline Soon: Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz is reminding Capricor Therapeutics, Inc. (CAPR) investors of a September 28, 2026 deadline to join a securities fraud class action lawsuit. The lawsuit alleges that Capricor made misleading statements between December 17, 2025, and July 26, 2026, …

CAPR Investigation Notice: Capricor Therapeutics Hit with Securities Fraud Investigation over Clinical Data Misrepresentations – Investors Urged to Contact BFA Law

NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Capricor Therapeutics, Inc. (NASDAQ:CAPR) for potential securities fraud after its significant stock drop. If you invested in Capricor Therapeutics securities, you are encouraged …

Bronstein, Gewirtz & Grossman, LLC Encourages Americold Realty Trust, Inc. (COLD) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors in Americold Realty Trust, Inc. (COLD). This follows Americold's disclosure of a $305 million to $320 million non-cash impairment charge due to the termination and wind-down of operations at two retail …

COLD Investors Have Opportunity to Join Americold Realty Trust, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS) has initiated an investigation into Americold Realty Trust, Inc. (NYSE: COLD) following the company's announcement of a significant non-cash impairment charge. This charge, estimated between $305 million and $320 million, is due to the termination and wind-down of …

Dimensional Fund Advisors LP Raises Stake in Americold Realty Trust Inc. $COLD

Dimensional Fund Advisors LP increased its stake in Americold Realty Trust Inc. by 8.0% in the first quarter, now owning 4,002,156 shares valued at $45,865,000. Other institutional investors also adjusted their holdings, with hedge funds and institutional investors collectively owning 98.14% of the company's …

Earnings Update: Here's Why Analysts Just Lifted Their Pricol Limited (NSE:PRICOLLTD) Price Target To ₹835

Americold Realty Trust (COLD) Following Share Price Weakness Is The Growth Story A Bargain

(TCBK) Movement Within Algorithmic Entry Frameworks

The article analyzes Trico Bancshares (TCBK) through algorithmic entry frameworks, highlighting weak near-term sentiment but strong mid and long-term signals. It provides institutional trading strategies including position, momentum breakout, and risk hedging, along with detailed support and resistance levels across various timeframes. The analysis …

Capricor Investor News: If You Have Suffered Losses in Capricor Therapeutics Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, Aug. 02, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Capricor Therapeutics Inc. (NASDAQ: CAPR) resulting from allegations that Capricor may have issued materially …

Maxim Group Maintains Capricor Therapeutics(CAPR.US) With Hold Rating

Maxim Group has reiterated its Hold rating on Capricor Therapeutics (CAPR.US). The article does not provide specific details on the reasons for this rating or any financial metrics.

Wall Street Zen Downgrades Capricor Therapeutics (NASDAQ:CAPR) to Strong Sell

Wall Street Zen has downgraded Capricor Therapeutics (NASDAQ:CAPR) to a "strong sell" rating following a series of negative developments. The FDA's advisory committee voted against the effectiveness of Capricor's lead candidate, Deramiocel, and the company is facing securities-fraud investigations and shareholder lawsuits. Consequently, other …

Shareholder Alert - Robbins LLP Informs Investors of the Capricor Therapeutics, Inc. Class Action Lawsuit

Robbins LLP has filed a securities class action lawsuit against Capricor Therapeutics, Inc. on behalf of investors who purchased shares between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor misled investors regarding the FDA approval prospects for its lead product …

CAPR INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Capricor Therapeutics, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the Firm

A class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) alleging that the company made materially false or misleading statements regarding changes to the statistical analysis plan for Deramiocel and the FDA's lack of agreement to these changes, creating a significant …

Crédit Agricole S.A. gibt Ergebnisprognose für 2028 ab

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Americold Realty Trust, Inc. (COLD) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into Americold Realty Trust, Inc. (COLD) following the company's disclosure of a significant impairment charge. This charge, estimated between $305 million and $320 million, resulted from the termination and wind-down of operations at two of …

TCBK|Trico Bancshares|Price:57.900|Chg%:-0.010

This article provides a comprehensive stock analysis of Trico Bancshares (TCBK), highlighting its strong fundamentals, high growth potential, and relatively fair valuation. It notes high institutional ownership and recent "Hold" ratings from analysts, with expectations for an upward trend in the medium term. The …

SummitTX Capital L.P. Takes Position in Americold Realty Trust Inc. $COLD

SummitTX Capital L.P. has initiated a new position in Americold Realty Trust Inc. (NYSE:COLD) by purchasing 92,950 shares valued at approximately $1.07 million. Institutional investors now own 98.14% of the company, and analyst sentiment is mixed with a consensus "Hold" rating. Americold Realty Trust …

Capricor Therapeutics: FDA Advisory Panel Votes 9-3 That Evidence Does Not Support Deramiocel for DMD Cardiomyopathy

An FDA advisory committee voted 9-3 that the available evidence does not support the effectiveness of Deramiocel for Duchenne Muscular Dystrophy (DMD) cardiomyopathy. While this recommendation is non-binding, the FDA will consider it as part of the Biologics License Application (BLA) review, with the …

Crédit Agricole S.A. legt Ergebnisse für das zweite Quartal und das erste Halbjahr bis zum 30. Juni 2026 vor